Skip to Content

Oramed Pharmaceuticals Inc ORMP

Morningstar Rating
$2.55 +0.03 (1.19%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ORMP is trading at a 781% premium.
Price
$2.53
Fair Value
$8.24
Uncertainty
Extreme
1-Star Price
$96.51
5-Star Price
$3.48
Economic Moat
Xgfm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ORMP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.52
Day Range
$2.502.58
52-Week Range
$1.673.67
Bid/Ask
$2.42 / $2.60
Market Cap
$103.60 Mil
Volume/Avg
36,120 / 126,048

Key Statistics

Price/Earnings (Normalized)
Price/Sales
154.92
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
< 0.01%

Company Profile

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
15

Comparables

Valuation

Metric
ORMP
INVA
ENTA
Price/Earnings (Normalized)
10.59
Price/Book Value
0.621.531.83
Price/Sales
154.924.724.14
Price/Cash Flow
8.77
Price/Earnings
ORMP
INVA
ENTA

Financial Strength

Metric
ORMP
INVA
ENTA
Quick Ratio
5.268.516.23
Current Ratio
5.2810.426.43
Interest Coverage
9.81−12.14
Quick Ratio
ORMP
INVA
ENTA

Profitability

Metric
ORMP
INVA
ENTA
Return on Assets (Normalized)
−2.79%15.69%−25.87%
Return on Equity (Normalized)
−3.46%29.88%−50.83%
Return on Invested Capital (Normalized)
−7.62%17.71%−46.23%
Return on Assets
ORMP
INVA
ENTA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
VjjtyzmhFvxtp$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
KphxjqyxjTmtplz$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
NkzfjpzbTwzjdk$117.2 Bil
Moderna Inc
MRNA
KzmzjvbMbqf$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
RcplnttLjgzdwf$30.1 Bil
argenx SE ADR
ARGX
NbcysnhHtfs$27.8 Bil
BioNTech SE ADR
BNTX
HtdfjrlKkyfd$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
QbhmcvsxcCgbgmf$16.0 Bil
United Therapeutics Corp
UTHR
PyfgyktvfWrhfx$14.6 Bil
Incyte Corp
INCY
QzdksbsGjwyjf$13.0 Bil

Sponsor Center